Vertin contains betahistine hydrochloride that acts as a histamine agonist (triggers histamine) and a vasodilator (dilate blood vessels). Stimulation of the H1-receptors in the inner ear causes a vasodilatory effect and an increased permeability in the blood vessels which results in reduced endolymphatic pressure. Thus, Vertin improves the microcirculation of the labyrinth (part of inner ear), resulting in reduced pressure. This aids in restoring proper balance and decrease in vertigo symptoms.
Vertin is available in three strengths, 8 mg, 16 mg and 24 mg.
It is a commonly prescribed medicine for patients with balance disorders. It is used to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere’s disease.
Vertin is a product of Abbott, a multinational pharmaceutical company that
functions in various therapy areas. The company has a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. The company operates in more than 150 countries globally.
Benign paroxysmal positional vertigo (BPPV) is one of the most common causes of vertigo — the sudden sensation that you’re spinning or that the inside of your head is spinning.
Benign paroxysmal positional vertigo causes brief episodes of mild to intense dizziness. Benign paroxysmal positional vertigo is usually triggered by specific changes in the position of your head. This might occur when you tip your head up or down, when you lie down, or when you turn over or sit up in bed.
The signs and symptoms of benign paroxysmal positional vertigo (BPPV) may include:
A sense that you or your surroundings are spinning or moving (vertigo)
A loss of balance or unsteadiness
The signs and symptoms of BPPV can come and go, with symptoms commonly lasting less than one minute. Episodes of benign paroxysmal positional vertigo can disappear for some time and then recur.
As directed by your physician
As directed by your physician
Adverse Reactions/ Side Effects
Significant: Rarely, ventricular extrasystoles, hypotension (including orthostatic hypotension), tachycardia. Gastrointestinal disorders: Nausea, dyspepsia. Rarely, vomiting, bloating, abdominal distension or pain. General disorders and administration site conditions: Rarely, fatigue, malaise. Immune system disorders: Hypersensitivity reactions (e.g. anaphylaxis). Rarely, urticaria. Nervous system disorders: Headache. Rarely, dizziness, convulsions, somnolence. Psychiatric disorders: Rarely, confusion, hallucination. Respiratory, thoracic and mediastinal disorders: Rarely, dyspnoea, bronchospasm. Skin and subcutaneous tissue disorders: Rarely, rash, pruritus. Vascular disorders: Rarely, vasodilation.
Warnings and Precautions
Patients with bronchial asthma, CV disease, active or history of peptic ulcer disease. Hepatic impairment. Pregnancy and lactation.
Serum concentration may be increased by MAOIs (e.g. selegiline). Therapeutic effects may be decreased by antihistamines. May decrease the bronchodilator effects of β2 agonists.
Oral: Store below 25°C. Protect from moisture and light.
Mechanism of Action
Betahistine is a histamine analogue. The exact mechanism is not yet fully determined; however, it is known to act as both partial histamine H1-receptor agonist and histamine H3-receptor antagonist in neuronal tissue, with negligible histamine H2-receptor activity. It may also improve the microcirculation in the labyrinth, thus reducing endolymphatic pressure.